Arrowhead Pharmaceuticals, Inc. reported $669M of revenue over the trailing twelve months, +17% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $669M (to Q3 2026). Net income: −$320M, trailing twelve months to Q3 2026. Free cash flow: −$75M, trailing twelve months to Q3 2026. Operating margin: −96%, trailing twelve months to Q3 2026.

ARWRArrowhead Pharmaceuticals, Inc.

Healthcare

$62.78+105% 1Y

$62.78

$31.6652 weeks$89.61

ARWR as reported

Arrowhead Pharmaceuticals, Inc. reported $669M of revenue over the trailing twelve months, +17% on the year before. 10 reported series are charted on this page, each one as filed.

$669M

Revenue, trailing twelve months · to Q3 2026 · +17% against the twelve months before

Net income: −$320M
Net income · +116% year on year · trailing twelve months to Q3 2026
Free cash flow: −$75M
Free cash flow · +326% year on year · trailing twelve months to Q3 2026
Operating margin: −96%
Operating margin · trailing twelve months to Q3 2026

Details›

Every series Ryufin has for ARWR, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$669M	+17%	Q3 2026
Net income	−$320M	+116%	Q3 2026
EPS	−$2.25	+77%	Q3 2026
Operating margin	−96%	n/a	Q3 2026
Net margin	−109%	n/a	Q3 2026
ROE	−21%	n/a	Q3 2026
ROA	−4.0%	n/a	Q3 2026
ROIC	−16%	n/a	Q3 2026
Free cash flow	−$75M	+326%	Q3 2026
P/E	126	n/a	Q2 2020 · 25 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.